{
    "symbol": "AMGN",
    "slug": "amgn",
    "display_name": "AMGN",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/amgn",
    "lang": "en",
    "as_of": "2026-06-26T15:30:06+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 7,
        "avg_confidence": 85,
        "last_signal_at": "2026-06-26 14:50:52",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "European regulators' recommendation to withdraw Tavneos",
            "count": 1
        },
        {
            "text": "Data integrity probe findings",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Amgen successfully appeals the decision or submits new data to overturn the withdrawal",
            "count": 1
        },
        {
            "text": "The EU withdrawal has limited financial impact if Tavneos sales are minimal",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-06-26 14:50:52",
            "sentiment": "Bearish",
            "impact_score": 7,
            "confidence_score": 85,
            "mention_type": "explicit",
            "timeframe": "short-term",
            "region": "US",
            "reasoning": "The article explicitly reports that European regulators backed Tavneos’ withdrawal due to data integrity issues. As Tavneos is an Amgen product, the decision directly threatens EU sales, which accounted for a meaningful portion of the drug’s revenue. This negative regulatory action is likely to weigh on Amgen’s stock in the short term.",
            "article": {
                "title": "Amgen’s Tavneos Faces EU Withdrawal After Data Integrity Probe",
                "url": "https://finscans.com/news/amgens-tavneos-faces-eu-withdrawal-after-data-integrity"
            }
        }
    ]
}